Summary

Florian Holsboer, director of the Max-Planck Institute for Psychiatry for 25 years, called for a reengineering of the drug development process for antidepressants, meaning a shift from a focus on blockbuster drugs capable of treating all depression to use of biomarkers to target subsets of patients based on disease etiology.